Sandu Pharmaceuticals Limited has taken a significant step towards restructuring its shareholder categories. The company's Board of Directors, in a meeting held on October 14, 2025, approved a postal ballot notice to seek shareholder approval for a key reclassification.

Reclassification Proposal

The board has proposed to reclassify M/s Akshath Finvest and Properties Private Limited from the 'Promoter/Promoter Group' category to the 'Public' category. This move, if approved by shareholders, could potentially alter the ownership structure of the company.

Postal Ballot Details

Key details of the postal ballot process are as follows:

Process and Compliance

The company has emphasized its commitment to regulatory compliance in this process:

1. The postal ballot notice will be sent electronically to members whose email addresses are registered with the company or depositories.
2. The cut-off date of October 15, 2025, has been set to determine member eligibility for electronic voting.
3. The process adheres to Section 110 of the Companies Act 2013 and relevant SEBI regulations.

Implications

This reclassification, if approved, could have significant implications for Sandu Pharmaceuticals' shareholding pattern and potentially its governance structure. Shareholders will play a crucial role in this decision through their participation in the e-voting process.

Investors and stakeholders of Sandu Pharmaceuticals Limited should closely monitor this development and its potential impact on the company's future direction.

Sandu Pharmaceuticals Limited , a Goa-based pharmaceutical manufacturer, has reported a mixed set of financial results for the first quarter. The company achieved significant profitability improvements despite a marginal decline in revenue.

Key Financial Highlights

• Total income decreased by 2.2% to ₹1,671.67 lakhs compared to ₹1,709.03 lakhs in the same quarter last year.
• Net profit before tax rose by 25% to ₹33.87 lakhs.
• Net profit after tax surged by 33.8% to ₹22.33 lakhs.
• Earnings per share improved from ₹0.17 to ₹0.23.

Improved Profitability Amid Revenue Challenges

Despite the slight dip in total income, Sandu Pharmaceuticals demonstrated notable improvements in its bottom line. The company's net profit after tax saw a substantial increase of 33.8%, rising from ₹16.69 lakhs to ₹22.33 lakhs. This growth in profitability, coupled with the increase in earnings per share from ₹0.17 to ₹0.23, suggests effective cost management and operational efficiency.

Revenue Performance

The company's total income for the quarter stood at ₹1,671.67 lakhs, representing a 2.2% decrease from the ₹1,709.03 lakhs reported in the corresponding quarter of the previous fiscal year. While this marginal decline in revenue presents a challenge, the company's ability to significantly boost profitability in this environment is noteworthy.

Operational Efficiency

The improved profitability metrics, despite the revenue decline, indicate that Sandu Pharmaceuticals has likely implemented effective cost-control measures and enhanced its operational efficiency. The company's operating profit margin (OPM) for the quarter was reported at 3.17%, which, although slightly lower than the previous quarter's 3.2%, demonstrates the company's ability to maintain relatively stable margins in a challenging revenue environment.

Management Approval and Disclosure

The financial results were approved by the company's board of directors on August 13, and subsequently published in newspapers on August 15, as per regulatory requirements. This prompt disclosure aligns with the company's commitment to transparency and compliance with listing obligations.

Looking Ahead

While the revenue decline may be a point of concern, the significant improvement in profitability suggests that Sandu Pharmaceuticals is navigating the current market conditions effectively. The company's ability to enhance its bottom line in a challenging revenue environment may position it well for future growth as market conditions improve.

Investors and stakeholders will likely be watching closely to see if the company can maintain this improved profitability while also working to reverse the trend in revenue in the coming quarters.